Access cutting-edge scleroderma treatment through this clinical trial at a research site in Birmingham. Study-provided care at no cost to qualified participants.
Access scleroderma specialists in Birmingham at no cost
This study follows strict safety protocols and ethical guidelines
All study-related scleroderma treatment provided free
The purpose of this study is to evaluate the efficacy and safety of treatment with subcutaneous anifrolumab versus placebo in adult participants with systemic sclerosis. The target population for this study includes patients who meet the 2013 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) classification for systemic sclerosis, either limited or diffuse cutaneous subsets, with a disease duration of less than 6 years from first non-Raynaud's phenomenon symptom.
Sponsor: AstraZeneca
Check if you qualify for this scleroderma clinical trial in Birmingham, AL
If you're searching for scleroderma treatment options in Birmingham, AL, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Birmingham research site is actively enrolling participants for this clinical trial. You'll receive care from experienced scleroderma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.